Katharine Peterson - May 13, 2024 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Accounting Officer
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
May 13, 2024
Transactions value $
$0
Form type
3
Date filed
5/16/2024, 06:52 PM
Next filing
May 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACRV Common Stock 4.83K May 13, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRV Stock Option (Right to Buy) May 13, 2024 Common Stock 56.8K $4.07 Direct F2
holding ACRV Stock Option (Right to Buy) May 13, 2024 Common Stock 16K $12.50 Direct F3
holding ACRV Stock Option (Right to Buy) May 13, 2024 Common Stock 17.7K $5.70 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares include 3,672 restricted stock units ("RSUs") from an original grant of 5,341 RSUs on November 14, 2022. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of the original 5,341 RSUs granted, twenty-five percent (25%) vested on November 14, 2023, and the remaining RSUs vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F2 Twenty-five percent (25%) of the shares subject to the option vested on July 11, 2023, and the remaining shares subject to the option vest in 12 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F3 Twenty-five percent (25%) of the shares subject to the option vested on November 14, 2023, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F4 Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney